Gavin MacBeath is the Chief Executive Officer of TScan Therapeutics, Inc., a role he stepped into on May 24, 2023, after serving as the acting CEO since March 2023. With a Ph.D. from The Scripps Research Institute, he brings a...

Gavin MacBeath is the Chief Executive Officer of TScan Therapeutics, Inc., a role he stepped into on May 24, 2023, after serving as the acting CEO since March 2023. With a Ph.D. from The Scripps Research Institute, he brings a strong scientific background to his leadership. Prior to TScan, Dr. MacBeath held significant roles in various biotech companies including Abpro Corporation and Merrimack Pharmaceuticals, where he worked on advancing key therapies. Known for his insights in drug development and research innovation, he has over two decades of experience in both academia and the biotech industry. In 2023, his total compensation was reported at approximately $3.2 million, including a salary of $545,121 and significant stock options, reflecting his value to the company. Dr. MacBeath's career showcases his commitment to science and innovation in healthcare, pivotal for TScan as it develops therapies that address significant medical needs.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other TScan Therapeutics, Inc. CEOs

T

Gavin MacBeath

CEO of TScan Therapeutics, Inc.

Education

Ph.D. from The Scripps Research Institute

Field of Expertise

Other - Science

Sector of Economy

Healthcare

Born

January 1, 1969 - 56 years ago

CEO of TScan Therapeutics, Inc. for

1 year 11 months (May 2023 - Present)

Previous Experience

Chief Scientific Officer at Abpro Corporation

Rivals

Competitors/colleagues of Gavin MacBeath

Holdings

See how much did Gavin MacBeath make over time.

As of 2023, Gavin MacBeath holds stock options for 1,121,300 shares of TScan Therapeutics. His stock holdings have seen fluctuations since he joined TScan, with options value being significant, estimated around $2.49 per share at the time of his stock...

As of 2023, Gavin MacBeath holds stock options for 1,121,300 shares of TScan Therapeutics. His stock holdings have seen fluctuations since he joined TScan, with options value being significant, estimated around $2.49 per share at the time of his stock option grant. This indicates a strong vested interest in the company's future success, as his wealth in TScan's stock is contingent upon the company's performance and growth. Specifically, Dr. MacBeath has seen considerable value in his options, as reflected in his prior roles in the biotech sector. His engagement in stock options helps align his interests with those of the shareholders, emphasizing a commitment to driving the company forward.

Insider Trading

See recent insider trades of Gavin MacBeath.

TCRX

$31.02K

TCRX at $6.20/share

Sep 20, 2021

Purchase

Compensation History

See how much did Gavin MacBeath make over time.

In 2023, Gavin MacBeath received total compensation amounting to approximately $3.2 million, marking a significant position within TScan Therapeutics. His base salary was $545,121, and though eligible for a bonus based on performance goals, he did not receive a bonus for that year. The majority of his compensation comes from stock options valued at $2.34 million, showcasing his potential substantial financial upside tied to the company’s success. His compensation aligns with TScan’s performance-focused philosophy, designed to attract and retain top talent in a competitive biotechnology landscape. This package reflects the importance of his role in leading TScan as it navigates complex drug development phases.

Year

2023

Total Compensation

$853.51K

Salary

$545.12K

Board Justification

The compensation philosophy aligns with company performance and aims to attract and retain top talent in a competitive market.

Bonus

$0.00

Board Justification

Dr. MacBeath is eligible to earn an incentive bonus based on individual performance goals and achievement of corporate goals, but no bonus was awarded for 2023.

Other

$308.39K

Board Justification

This includes retirement plan contributions and other benefits paid to Dr. MacBeath.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was reported as vested in 2023.

Performance Metrics

The performance metrics for determining Dr. MacBeath's compensation include individual performance goals and achievement of corporate goals related to product development.

Other TScan Therapeutics, Inc. CEOs

Here are other CEOs of TScan Therapeutics, Inc.

David Southwell

Ex-CEO of TScan Therapeutics, Inc.

April 2021 - March 2023